Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The study objectives are to evaluate the safety and efficacy of the oral administration of
lenalidomide in combination with dexamethasone in the treatment of adult patients with
refractory or relapsed non-Ph+ B-cell lineage acute lymphoblastic leukemia (ALL).